Journal of Vascular and Interventional Radiology最新文献

英文中文

Crossword Puzzle 纵横字谜游戏

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-05 DOI: 10.1016/j.jvir.2025.107956

引用次数: 0

Crossword Puzzle: Answer Key 填字游戏：回答关键

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-05 DOI: 10.1016/j.jvir.2025.107955

引用次数: 0

Percutaneous Adrenal Biopsies in Patients with Cancer: The Utility of Preprocedural Endocrine Workup 经皮肾上腺活检在癌症患者：术前内分泌检查的效用。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-03 DOI: 10.1016/j.jvir.2025.107989

Erez Klein MD , Marcell Gyano MD, PhD , Vaiva Gustainyte DO , Junsung Choi MD , Bela Kis MD, PhD

Purpose

To assess the safety of adrenal biopsies in patients with known or suspected malignancies without preprocedural endocrine evaluations.

Materials and Methods

This was a single-center retrospective study that included 426 patients (249 men and 177 women; mean age, 66.1 years [SD ± 11.0]) with known or suspected malignancy who underwent 487 computed tomography (CT)–guided adrenal biopsies between October 2011 and December 2023. The authors analyzed medical records and cross-sectional imaging, evaluating technical and diagnostic success rates as well as complications.

Results

Of the 487 biopsies, 442 (91%) were performed in patients with confirmed malignancies, whereas 45 cases (9%) were patients presenting with new abdominal or lung mass and adrenal mass. The most common primary malignancy was lung cancer (272 of 487, 56%). Technical success rate was 99.8% (486 of 487), with a diagnostic success rate of 97.1% (473 of 487). Histopathological findings differed from known primary malignancy in 2.9% (14 of 487) of cases. Endocrine assessments were performed before 40 biopsies (8.2%). Three (3 of 487, 0.61%) new histological diagnoses of pheochromocytoma emerged, with 2 (66%) occurring in patients with known malignancies. A total of 45 adverse events (9.2%) were observed, primarily Grades 1–2, with only 6 classified as Grade 3 (4 hemorrhages and 2 cases of hypertension). Only 1 case of Grade 3 hypertension linked to pheochromocytoma.

Conclusions

Incidence of pheochromocytoma in patients with known or suspected extra-adrenal malignancies without endocrine workup was less than 1%. Therefore, endocrine workup prior to adrenal biopsies in patients with known and suspected malignancies may not be indicated despite recommendations of international guidelines.

目的：本研究旨在评估没有术前内分泌评估的已知或疑似恶性肿瘤患者肾上腺活检的安全性。方法：这是一项单中心回顾性研究，纳入了426例已知或疑似恶性肿瘤患者（249例男性，177例女性，平均年龄：66.1±11.0岁），这些患者在2011年10月至2023年12月期间接受了487次ct引导下的肾上腺活检。我们分析了医疗记录和横断面成像，评估了技术和诊断的成功率以及并发症。结果：在487例活检中，442例（91%）为确诊恶性肿瘤患者，而45例（9%）为出现新的腹部或肺部肿块和肾上腺肿块的患者。最常见的原发恶性肿瘤是肺癌（272/487,56%）。技术成功率为99.8%(486/487)，诊断成功率为97.1%（473/487）。在2.9%的病例（14/487）中，组织病理学结果与已知的原发性恶性肿瘤不同。40例（8.2%）活检前进行内分泌评估。出现3例（3/487,0.61%）嗜铬细胞瘤的组织学新诊断，其中2例（66%）发生在已知恶性肿瘤患者中。共观察到45例不良事件（9.2%），主要为1-2级，仅6例为3级（4例出血和2例高血压）。只有1例3级高血压与嗜铬细胞瘤有关。结论：已知或疑似肾上腺外恶性肿瘤而未进行内分泌检查的患者嗜铬细胞瘤的发生率低于1%。因此，尽管有国际指南的建议，已知和疑似恶性肿瘤的患者在肾上腺活检前可能不需要进行内分泌检查。

{"title":"Percutaneous Adrenal Biopsies in Patients with Cancer: The Utility of Preprocedural Endocrine Workup","authors":"Erez Klein MD , Marcell Gyano MD, PhD , Vaiva Gustainyte DO , Junsung Choi MD , Bela Kis MD, PhD","doi":"10.1016/j.jvir.2025.107989","DOIUrl":"10.1016/j.jvir.2025.107989","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess the safety of adrenal biopsies in patients with known or suspected malignancies without preprocedural endocrine evaluations.</div></div><div><h3>Materials and Methods</h3><div>This was a single-center retrospective study that included 426 patients (249 men and 177 women; mean age, 66.1 years [SD ± 11.0]) with known or suspected malignancy who underwent 487 computed tomography (CT)–guided adrenal biopsies between October 2011 and December 2023. The authors analyzed medical records and cross-sectional imaging, evaluating technical and diagnostic success rates as well as complications.</div></div><div><h3>Results</h3><div>Of the 487 biopsies, 442 (91%) were performed in patients with confirmed malignancies, whereas 45 cases (9%) were patients presenting with new abdominal or lung mass and adrenal mass. The most common primary malignancy was lung cancer (272 of 487, 56%). Technical success rate was 99.8% (486 of 487), with a diagnostic success rate of 97.1% (473 of 487). Histopathological findings differed from known primary malignancy in 2.9% (14 of 487) of cases. Endocrine assessments were performed before 40 biopsies (8.2%). Three (3 of 487, 0.61%) new histological diagnoses of pheochromocytoma emerged, with 2 (66%) occurring in patients with known malignancies. A total of 45 adverse events (9.2%) were observed, primarily Grades 1–2, with only 6 classified as Grade 3 (4 hemorrhages and 2 cases of hypertension). Only 1 case of Grade 3 hypertension linked to pheochromocytoma.</div></div><div><h3>Conclusions</h3><div>Incidence of pheochromocytoma in patients with known or suspected extra-adrenal malignancies without endocrine workup was less than 1%. Therefore, endocrine workup prior to adrenal biopsies in patients with known and suspected malignancies may not be indicated despite recommendations of international guidelines.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 4","pages":"Article 107989"},"PeriodicalIF":2.6,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Crossword Puzzle 纵横字谜游戏

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.107914

引用次数: 0

Cryoablation Protocols for Primary and Metastatic Lung Tumors: A Systematic Review and Meta-Analysis Evaluating Effectiveness and Safety of Percutaneous Cryoablation of Pulmonary Tumors 原发性和转移性肺肿瘤的冷冻消融方案：一项评估经皮肺肿瘤冷冻消融有效性和安全性的系统综述和荟萃分析。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.004

Arman Sarshoghi , Arash Sarshoghi MSc , Maxime Têtu MSc , Calvin S.H. Ng MD , Lonny Yarmus DO , Patrick Bourgouin MD , Stephen B. Solomon MD , Felix Herth MD, PhD , Robert P. Liddell MD , Moishe Liberman MD, PhD

Purpose

To evaluate 1-year local tumor control (LTC) after percutaneous cryoablation for lung tumors and to identify procedural protocol and patient/tumor characteristics associated with improved outcomes.

Materials and Methods

A systematic search of PubMed, Embase, and Web of Science was conducted. The primary outcome was LTC at 1 year. Secondary outcomes included the identification of factors associated with LTC and pooled adverse event rates, such as freezing lengths, number of cycles, tumor characteristics, and more. Data were pooled using a random-effects model, and meta-regression was used to analyze factors affecting LTC.

Results

Nineteen studies (786 patients, 1,048 tumors) yielded a pooled 1-year LTC of 90.5% (95% CI, 85.1%–94.1%). Multivariate meta-regression showed that smaller tumor size was significantly associated with improved LTC. Univariate analysis also identified that superior LTC was associated with a triple freeze-thaw protocols (vs double), a shorter first freeze duration, a longer final freeze duration, and ending the procedure with a thaw cycle. The incidence of adverse events (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≥3) was 4.9% (95% CI, 2.9%–6.9%), with pneumothorax most common (28% of cases).

Conclusions

Percutaneous cryoablation demonstrates high effectiveness for lung tumor control. Superior 1-year LTC is associated with smaller tumor size and a triple freeze-thaw protocol characterized by a short initial freeze followed by longer subsequent freezes. These findings provide a data-driven basis for standardizing cryoablation techniques.

目的：本系统综述和荟萃分析旨在评估经皮肺肿瘤冷冻消融后1年的局部肿瘤控制（LTC），并确定与改善预后相关的手术方案和患者/肿瘤特征。方法：系统检索PubMed、EMBASE和Web of Science。主要终点为1年LTC。次要结局包括确定与LTC和汇总不良事件发生率相关的因素，如冷冻时间、周期数、肿瘤特征等。采用随机效应模型对数据进行汇总，并采用元回归分析影响LTC的因素。结果：19项研究（786例患者，1048个肿瘤）得出的1年总LTC为90.5% （95% CI, 85.1%-94.1%）。多变量荟萃回归显示，较小的肿瘤大小与LTC改善显著相关。单变量分析还发现，较好的LTC与三次冻融方案（与两次冻融方案相比）、较短的首次冻融持续时间、较长的最终冻融持续时间以及以解冻周期结束的过程有关。不良事件（CTCAE分级≥3）发生率为4.9% (95% CI: 2.9%-6.9%)，其中气胸最为常见（28%的病例）。结论：经皮冷冻消融治疗肺肿瘤疗效显著。优越的1年LTC与较小的肿瘤大小和三重冻融方案相关，其特征是初始冻结时间短，随后冻结时间长。这些发现为标准化冷冻消融技术提供了数据驱动的基础。

{"title":"Cryoablation Protocols for Primary and Metastatic Lung Tumors: A Systematic Review and Meta-Analysis Evaluating Effectiveness and Safety of Percutaneous Cryoablation of Pulmonary Tumors","authors":"Arman Sarshoghi , Arash Sarshoghi MSc , Maxime Têtu MSc , Calvin S.H. Ng MD , Lonny Yarmus DO , Patrick Bourgouin MD , Stephen B. Solomon MD , Felix Herth MD, PhD , Robert P. Liddell MD , Moishe Liberman MD, PhD","doi":"10.1016/j.jvir.2025.10.004","DOIUrl":"10.1016/j.jvir.2025.10.004","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate 1-year local tumor control (LTC) after percutaneous cryoablation for lung tumors and to identify procedural protocol and patient/tumor characteristics associated with improved outcomes.</div></div><div><h3>Materials and Methods</h3><div>A systematic search of PubMed, Embase, and Web of Science was conducted. The primary outcome was LTC at 1 year. Secondary outcomes included the identification of factors associated with LTC and pooled adverse event rates, such as freezing lengths, number of cycles, tumor characteristics, and more. Data were pooled using a random-effects model, and meta-regression was used to analyze factors affecting LTC.</div></div><div><h3>Results</h3><div>Nineteen studies (786 patients, 1,048 tumors) yielded a pooled 1-year LTC of 90.5% (95% CI, 85.1%–94.1%). Multivariate meta-regression showed that smaller tumor size was significantly associated with improved LTC. Univariate analysis also identified that superior LTC was associated with a triple freeze-thaw protocols (vs double), a shorter first freeze duration, a longer final freeze duration, and ending the procedure with a thaw cycle. The incidence of adverse events (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≥3) was 4.9% (95% CI, 2.9%–6.9%), with pneumothorax most common (28% of cases).</div></div><div><h3>Conclusions</h3><div>Percutaneous cryoablation demonstrates high effectiveness for lung tumor control. Superior 1-year LTC is associated with smaller tumor size and a triple freeze-thaw protocol characterized by a short initial freeze followed by longer subsequent freezes. These findings provide a data-driven basis for standardizing cryoablation techniques.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107871"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-Session Ethanol Sclerotherapy for Symptomatic Simple Adrenal Cysts 单期乙醇硬化疗法治疗单纯性肾上腺囊肿。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.008

Peter M. Do BS , James Y. Lim MD , Keith B. Quencer MD , Brian J. Park MD, MS

引用次数: 0

Cover 封面

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/S1051-0443(25)00787-0

引用次数: 0

Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases 肿瘤吸收剂量、代谢反应和乳腺癌肝转移患者放射栓塞后的生存。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.045

Osman Melih Topcuoğlu MD , Türkay Toklu , Nalan Alan Selçuk MD , Betül Uzunoğlu MD

Purpose

To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (⁹⁰Y) transarterial radioembolization (TARE).

Materials and Methods

Between August 2016 and August 2024, patients with BCLM who underwent ⁹⁰Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression–free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.

Results

Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3–9.0 months) and 4.2 months (IQR, 2.5–5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (P = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5–14.8 months) and 4.1 months (IQR, 3.1–6.3 months) versus 4.0 months (IQR, 2.5–4.5 months) and 2.1 months (IQR, 1.3–2.7 months), respectively (P = .025 and P = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (P = .024 and P = .397, respectively).

Conclusions

Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.

目的：探讨经动脉放射栓塞（TARE）治疗乳腺癌肝转移（BCLM）患者肿瘤吸收剂量（TAD）与肿瘤反应及生存期的关系。方法与材料：回顾性分析2016年8月至2024年8月间行玻璃颗粒Y90-TARE治疗的BCLM患者。主要结局是总生存期（OS）和肝脏无进展生存期（hPFS）。次要终点为客观有效率。使用实体瘤正电子发射断层扫描反应标准（PERCIST）评估对治疗的反应。患者分为有反应组和无反应组。结果或发现：42例女性中有26例患者符合纳入标准，平均年龄为57.9±13.8岁。所有患者的中位OS和hPFS分别为6.1个月（IQR; 4.3-9.0个月）和4.2个月（IQR; 2.5-5.6个月）。应答者和无应答者的中位TAD分别为157 Gy和150 Gy （p=0.768）。应答者与无应答者的中位OS和hPFS分别为8.3个月（IQR; 5.5-14.8个月）和4.1个月（IQR; 3.1-6.3个月），而4.0个月（IQR; 2.5-4.5个月）和2.1个月（IQR; 1.3-2.7个月），分别为（p= 0.025和p= 0.210）。在145 Gy以上，TAD表现出显著的OS获益，但没有改变肝脏hPFS （p = 0.024和p = 0.397）。结论：在本研究中，影像学反应与OS有一定相关性，而TAD与反应无相关性。

{"title":"Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases","authors":"Osman Melih Topcuoğlu MD , Türkay Toklu , Nalan Alan Selçuk MD , Betül Uzunoğlu MD","doi":"10.1016/j.jvir.2025.08.045","DOIUrl":"10.1016/j.jvir.2025.08.045","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (<sup>90</sup>Y) transarterial radioembolization (TARE).</div></div><div><h3>Materials and Methods</h3><div>Between August 2016 and August 2024, patients with BCLM who underwent <sup>90</sup>Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression–free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.</div></div><div><h3>Results</h3><div>Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3–9.0 months) and 4.2 months (IQR, 2.5–5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (<em>P</em> = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5–14.8 months) and 4.1 months (IQR, 3.1–6.3 months) versus 4.0 months (IQR, 2.5–4.5 months) and 2.1 months (IQR, 1.3–2.7 months), respectively (<em>P</em> = .025 and <em>P</em> = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (<em>P</em> = .024 and <em>P</em> = .397, respectively).</div></div><div><h3>Conclusions</h3><div>Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107833"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasound Fusion in Interventional Radiology: A Practical Guide to Procedural Applications 介入放射学中的超声融合：程序应用的实用指南。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.016

Benjamin York MD , Bryce D. Beutler MD , Lenora M. Lewis MD , Ellen Y. Chang MD, MS , Ishan Shah BS , April Ballard MD , Brittany J. Kazmierski MD , Samantha S. Chau MD , Hisham Tchelepi MD

Ultrasound (US) fusion, defined as coregistration of cross-sectional images and real-time planar US, has emerged as a powerful tool to enhance the safety and accuracy of image-guided interventions. Computed tomography (CT), magnetic resonance (MR) imaging, and positron emission tomography (PET) can be integrated with conventional US using fusion navigation software, which is available from most major vendors. The US fusion technique enables precise intraprocedural localization of target lesions. The software is broadly accessible, intuitive to use, and suitable for implementation by both interventional and diagnostic radiologists in community and academic settings. In this narrative review, the authors present a comprehensive overview of US fusion–guided interventions, detailing the technical approach and providing case examples from a major teaching hospital.

超声融合被定义为横截面图像和实时平面超声的共同配准，已成为增强图像引导干预的安全性和准确性的有力工具。计算机断层扫描（CT）、磁共振成像（MRI）和正电子发射断层扫描（PET）可以使用融合导航软件与传统超声波集成，这些软件可以从大多数主要供应商那里获得。超声融合技术可以在术中精确定位目标病变。该软件易于访问，使用直观，适合社区和学术环境中的介入和诊断放射科医生实施。在这篇叙述性的综述中，我们提出了超声融合引导干预的全面概述，详细介绍了技术方法，并提供了来自一家大型教学医院的案例。

引用次数: 0

Abernethy Malformation Shunt Closure to Treat Hepatic Encephalopathy Mimicking Parkinson Disease 畸形分流关闭治疗模拟帕金森病肝性脑病。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.043

Rasmiranjan Padhi MBBS, MD , Arun Prasannan MBBS, MD , Virag Shethna MBBS, MD , Jagadeesan Dhanasekaran MBBS, MD , Shanmuga Sundaram Radhakrishnan MBBS, MD

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Vascular and Interventional Radiology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀